WASHINGTON — In the first randomized trial of a therapy for treatment of patients with angina and nonobstructive CAD, diltiazem did not improve coronary vasomotor dysfunction compared with placebo.
For the EDIT-CMD trial, researchers randomly assigned 85 patients with angina and nonobstructive CAD (ANOCA) who underwent coronary function testing to receive up to 360 mg diltiazem or placebo per day.
“ANOCA patients have worse prognosis compared with asymptomatic patients,” Tijn P.J. Jansen, MD, PhD candidate in the department of cardiology at Radboud University Medical Center,